
Katherine McMahan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4278784/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature, 2021, 590, 630-634.	13.7	995
2	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.	6.0	978
3	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.	6.0	789
4	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.	13.7	765
5	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature, 2022, 603, 493-496.	13.7	326
6	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA - Journal of the American Medical Association, 2021, 325, 2370.	3.8	307
7	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature, 2021, 596, 268-272.	13.7	290
8	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nature Medicine, 2020, 26, 1694-1700.	15.2	275
9	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.	3.8	260
10	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature, 2018, 563, 360-364.	13.7	246
11	Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. New England Journal of Medicine, 2021, 385, 2010-2012.	13.9	228
12	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. New England Journal of Medicine, 2021, 385, 951-953.	13.9	192
13	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host and Microbe, 2019, 25, 59-72.e8.	5.1	124
14	Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters. Med, 2022, 3, 262-268.e4.	2.2	117
15	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Science Translational Medicine, 2017, 9, .	5.8	106
16	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature, 2022, 601, 410-414.	13.7	71
17	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	68
18	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell, 2022, 185, 1549-1555.e11.	13.5	59

KATHERINE MCMAHAN

#	Article	IF	CITATIONS
19	Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant. Science Translational Medicine, 2022, 14, eabn6150.	5.8	57
20	Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell, 2021, 184, 3467-3473.e11.	13.5	49
21	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature, 2021, 596, 423-427.	13.7	40
22	Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. Journal of Virology, 2021, 95, e0040421.	1.5	34
23	Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj3789.	5.8	32
24	Lack of therapeutic efficacy of an antibody to α ₄ β ₇ in SIVmac251-infected rhesus macaques. Science, 2019, 365, 1029-1033.	6.0	31
25	SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques. Science Advances, 2022, 8, eabl6015.	4.7	27
26	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. Nature Communications, 2021, 12, 1474.	5.8	26
27	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	13.5	25
28	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection. Journal of Virology, 2021, 95, .	1.5	24
29	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. Science Translational Medicine, 2021, 13, eabj2641.	5.8	15
30	Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals. Journal of Infectious Diseases, 2022, 225, 1124-1128.	1.9	15
31	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. PLoS Biology, 2022, 20, e3001609.	2.6	14
32	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques. Science Translational Medicine, 2022, 14, eabm4996.	5.8	13
33	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. Journal of Virology, 2021, 95, e0097421.	1.5	12
34	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. Npj Vaccines, 2022, 7, 23.	2.9	6
35	Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques. Journal of Virology, 2022, 96, JVI0159921.	1.5	5
36	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	2.9	4

#	Article	IF	CITATIONS
37	A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaques. Science Translational Medicine, 2022, 14, .	5.8	3
38	Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments. Veterinary Pathology, 2022, , 030098582210957.	0.8	2